DOJ withdraws motion against Ranbaxy
Pharma Compliance Alert, October 15, 2008
Generic drug maker Ranbaxy agreed to turn over audits to the Department of Justice (DOJ), and in response the DOJ withdrew a motion against the company. Ranbaxy initially claimed the audits, which were conducted by Parexel, were privileged.
On July 3, the Department of Justice (DOJ) filed a motion in U.S. District Court in Maryland seeking documents from Ranbaxy. In its filing, the DOJ alleged some of the products Ranbaxy manufactured were too strong, too weak, or lacked the proper shelf life. The DOJ also claims the FDA knew about the alleged problems for 18 months and did nothing to remove the products.
In September, the FDA issued two warning letters to Ranbaxy and issued import alerts covering various dosage forms and amounts for more than 30 different generic drugs. The FDA alleged Ranbaxy failed to follow good manufacturing practices in two of its facilities in India.
Comments
0 comments on “DOJ withdraws motion against Ranbaxy ”
Related Products
-
Medical Environment Update
Timely medical compliance news from OSHA, CDC, EPA, and other regulatory agencies!
-
Bloodborne Pathogens Training Video
Meets OSHA requirements for training employees on the bloodborne pathogens standard!
-
Hazard Communication Standard Training Video
Meets OSHA requirements for training employees on the Hazard Communication Standard!
-
Needlestick Prevention Training Video
Highlighting the five most frequent needlestick scenarios, this training video instructs frontline healthcare staff on on...
-
Complete Guide to Lab Safety, 3rd Ed.
The third edition of this popular resource makes training and compliance easier by consolidating regulations from all...
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- New FAQ posted on storing laryngoscope blades
- Q/A: Coding for telescopic intraocular lens
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- What does case-mix index mean to you?
- HHS task force: Consider privacy, security with text messages
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- "Wall fountains" may be spreading Legionnaires to patients, visitors
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- Searched